DCAD - Developing better diagnostics for Coronary Artery Disease with novel AI-enhanced, ultra fast proteomics

DCAD - 利用新型 AI 增强型超快速蛋白质组学开发更好的冠状动脉疾病诊断方法

• 批准号: 10072712
• 金额: $ 86.54万
• 依托单位: ELIPTICA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072712
• 关键词: DCAD; Developing; better; diagnostics; Coronary

**Developing novel proteomic techniques to improve early diagnostics for Coronary Heart Disease**Eliptica Limited proposes a 24 month programme of works based upon a new technique of AI-enhanced, ultrafast, low-cost mass-spectrometry (MS)-based proteomics that has been developed by its founders at the Francis Crick Institute and requires only very small amounts of blood plasma to perform high-quality, population scale, proteomic experiments.The project objective, with support from project partners Bruker UK Limited and UK Biobank, is to demonstrate that our platform can develop new insights into CVD through the application of AI to a large reference baseline of the human proteome and thus identify novel multi protein panel biomarkers (MPPB's) more quickly and accurately than is currently the case.Our MPPB's will be readily translatable into blood tests that more accurately identify patients at high risk of CVD (e.g. imminent risk of heart attack) or potentially identify the subset of patients most likely to benefit from a particular therapy. Eliptica was founded to enable Precision Medicine (i.e. to ensure the right patients receive the right treatments and medical interventions at the right time).

**Developing novel proteomic techniques to improve early diagnostics for Coronary Heart Disease**Eliptica Limited proposes a 24 month programme of works based upon a new technique of AI-enhanced, ultrafast, low-cost mass-spectrometry (MS)-based proteomics that has been developed by its founders at the Francis Crick Institute and requires only very small amounts of blood plasma to perform high-quality, population scale, proteomic实验目标。在项目合作伙伴布鲁克英国有限公司和英国生物库的支持下，项目目标是为了证明我们的平台可以通过将AI应用于大量的人类蛋白质组的大量参考基线来发展对CVD的新见解，从而更快地确定了更快地识别MPPB的疾病，从而更准确地识别了MPPB的预测。 CVD（例如，心脏病发作的迫在眉睫的风险）或有可能识别最有可能受益于特定疗法的患者的子集。 Eliptica的成立是为了使精确的医学（即确保正确的患者在正确的时间接受正确的治疗和医疗干预措施）。